Carmell Therapeutics Corporation is a biotechnology company focused on the development and commercialization of plasma-based bioactive materials (PBMs). Its proprietary PBMs are made from allogenic, platelet enriched plasma, which contains a concentration of growth factors that naturally stimulate wound repair. Carmell’s technology can be applied to address unmet needs across orthopedics, soft tissue healing, burns, dermatology, and other aspects of medicine.
Type | Private | |
Founded | 2007 | |
HQ | Pittsburgh, PA, US | Map |
Website | carmellrx.com |
Employees (est.) (Jan 2021) | 17 | |
Cybersecurity rating | C | More |
Founding Date | 2007 |
Carmell Therapeutics total Funding | $4.7 m |
Carmell Therapeutics latest funding size | $4 m |
Time since last funding | 4 years ago |
Carmell Therapeutics investors | BlueTree Capital Group, Pittsburgh Life Sciences Greenhouse, Harbor Light Capital, Newlin Investments, Keiretsu Forum Capital |
When was Carmell Therapeutics founded?
Carmell Therapeutics was founded in 2007.
Who are Carmell Therapeutics key executives?
Carmell Therapeutics's key executives are Randy Hubbell, James Hart and Janet M. Vargo.
How many employees does Carmell Therapeutics have?
Carmell Therapeutics has 17 employees.
Who are Carmell Therapeutics competitors?
Competitors of Carmell Therapeutics include CiMaas, Maravai LifeSciences and Regulaxis.
Where is Carmell Therapeutics headquarters?
Carmell Therapeutics headquarters is located at 2403 Sidney St #300, Pittsburgh.
Where are Carmell Therapeutics offices?
Carmell Therapeutics has an office in Pittsburgh.
How many offices does Carmell Therapeutics have?
Carmell Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies